MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer

Background MicroRNAs (miRs) are small RNA molecules, influencing messenger RNA (mRNA) expression and translation, and are readily detectable in blood. Some have been reported as potential breast cancer biomarkers. This study aimed to identify and validate miRs indicative of breast cancer. Results Based on the discovery and literature, 18 potentially informative miRs were quantified in the validation cohort. Irrespective of patient and tumour characteristics, hsa-miR-652-5p was significantly upregulated in the malignant compared to benign patients (1.26 fold, P = 0.005) and therefore validated as potential biomarker. In the validation cohort literature-based hsa-let-7b levels were higher in malignant patients as well (1.53 fold, P = 0.011). Two miRs differentiated benign wildtype from benign BRCA1 mutation carriers and an additional 8 miRs differentiated metastastic (n = 8) from non-metastatic (n = 41) cases in the validation cohort. Methods Pre-treatment plasma samples were collected of patients with benign breast disease and breast cancer and divided over a discovery (n = 31) and validation (n = 84) cohort. From the discovery cohort miRs differentially expressed between benign and malignant cases were identified using a 2,000-miR microarray. Literature-based miRs differentiating benign from malignant disease were added. Using RT-qPCR, their expression was investigated in a validation cohort consisting of pre-treatment benign, malignant and metastatic samples. Additionally, benign and malignant cases were compared to benign and malignant cases of BRCA1-mutation carriers. Conclusions Plasma microRNA levels differed between patients with and without breast cancer, between benign disease from wildtype and BRCA1-mutation carriers and between breast cancer with and without metastases. Hsa-miR-652-5p was validated as a potential biomarker for breast cancer.

[1]  Leping Li,et al.  The Diagnostic Efficacy and Biological Effects of microRNA-29b for Colon Cancer , 2016, Technology in cancer research & treatment.

[2]  T. Ochiya,et al.  Novel combination of serum microRNA for detecting breast cancer in the early stage , 2016, Cancer science.

[3]  P. Geurts,et al.  Circulating microRNA-based screening tool for breast cancer , 2015, Oncotarget.

[4]  Madeleine M A Tilanus-Linthorst,et al.  Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients , 2015, BMJ : British Medical Journal.

[5]  Juan Wu,et al.  Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females , 2015, Annals of laboratory medicine.

[6]  B. Tunca,et al.  BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer. , 2015, Gene.

[7]  Jingting Jiang,et al.  Prognostic Role of Tissue and Circulating MicroRNA-200c in Malignant Tumors: a Systematic Review and Meta-Analysis , 2015, Cellular Physiology and Biochemistry.

[8]  George A Calin,et al.  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients , 2014, Clinical Cancer Research.

[9]  K. Pantel,et al.  Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases , 2014, British Journal of Cancer.

[10]  B. Tunca,et al.  Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations , 2014, Molecular and Cellular Biochemistry.

[11]  Graham Ball,et al.  Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer , 2014, PloS one.

[12]  Michael Golatta,et al.  Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer , 2013, PloS one.

[13]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[14]  Yingjian Chen,et al.  Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[15]  Axel Benner,et al.  Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer , 2012, Clinical Cancer Research.

[16]  Evelyn Wenkel,et al.  Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection , 2012, PloS one.

[17]  S. Sleijfer,et al.  MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer , 2011, Breast Cancer Research and Treatment.

[18]  John W M Martens,et al.  mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients , 2011, Clinical Cancer Research.

[19]  S. Sleijfer,et al.  Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients , 2011, Expert review of molecular diagnostics.

[20]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[21]  John A. Foekens,et al.  Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR , 2009, Breast Cancer Research and Treatment.

[22]  Ulus Atasoy,et al.  Circulating microRNAs in breast cancer and healthy subjects , 2009, BMC Research Notes.

[23]  C. Croce,et al.  MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. , 2008, European journal of cancer.

[24]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[25]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[26]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[27]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[28]  B. Trock,et al.  Acceptability of Diagnostic Tests for Breast Cancer , 2003, Breast Cancer Research and Treatment.

[29]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[30]  T. Blondal,et al.  Assessing sample and miRNA profile quality in serum and plasma or other biofluids. , 2013, Methods.